Novel insights on GM1 and Parkinson's disease: A critical review

被引:0
|
作者
Maria Fazzari
Erika Di Biase
Giulia Lunghi
Laura Mauri
Elena Chiricozzi
Sandro Sonnino
机构
[1] University of Milan,Department of Medical Biotechnology and Translational Medicine
来源
Glycoconjugate Journal | 2022年 / 39卷
关键词
GM1 ganglioside; GM1 oligosaccharide; Parkinson's disease; Neuronale receptors;
D O I
暂无
中图分类号
学科分类号
摘要
GM1 is a crucial component of neuronal membrane residing both in the soma and nerve terminals. As reported in Parkinson’s disease patients, the reduction of GM1 determines the failure of fundamental functional processes leading to cumulative cell distress up to neuron death. This review reports on the role of GM1 in the pathogenesis of the disease, illustrating the current data available but also hypotheses on the additional mechanisms in which GM1 could be involved and which require further study. In the manuscript we discuss these points trying to explain the role of diminished content of brain GM1, particularly in the nigro-striatal system, in Parkinson’s disease etiology and progression.
引用
收藏
页码:27 / 38
页数:11
相关论文
共 50 条
  • [41] Insights into Binding of Cholera Toxin to GM1 Containing Membrane
    Basu, Ipsita
    Multhopadhyay, Chaitali
    LANGMUIR, 2014, 30 (50) : 15244 - 15252
  • [42] Gangliosidoses: Understanding disease evolution in GM1 and GM2
    Giugliani, Roberto
    Harmatz, Paul
    Heron, Benedicte
    Hahn, Andreas
    Patterson, Marc
    Bourchany, Aurelie
    Valle, Daniel A. D.
    Barone, Rita Maria Elisa
    Chabrol, Brigitte
    Ardissone, Anna
    Batzios, Spyros
    Scarpa, Maurizio
    Schneider, Susanne A.
    Carp, Nicoleta
    Freitag, Christian
    Gill, Aidan
    de Frutos, Laura Lopez
    MOLECULAR GENETICS AND METABOLISM, 2025, 144 (02)
  • [43] Effects of chronic GM1 ganglioside treatment on the progression of Parkinson's disease: Results of a two-year open study
    Schneider, JS
    Chapas-Crilly, J
    Mancall, EL
    NEUROLOGY, 1998, 50 (04) : A330 - A331
  • [44] Improvement of Parkinson's disease patients after GM1 ganglioside treatment: A double blind placebo-controlled study
    Schneider, JS
    Roeltgen, DP
    Mancall, EL
    Crilly, J
    Rothblat, DS
    Tatarian, GT
    NEUROLOGY, 1997, 48 (03) : 2003 - 2003
  • [45] CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson's disease (vol 15, 1122647, 2023)
    Wang, Rui
    Tong, Shanshan
    Wang, Mengdi
    Zou, Junjie
    Wang, Nan
    Sun, Fengjiao
    Zhou, Xiaosheng
    Chen, Jinbo
    Wang, Hongcai
    FRONTIERS IN AGING NEUROSCIENCE, 2023, 15
  • [46] Impaired Ganglioside Metabolism in Huntington's Disease and Neuroprotective Role of GM1
    Maglione, Vittorio
    Marchi, Paolo
    Di Pardo, Alba
    Lingrell, Susanne
    Horkey, Melanie
    Tidmarsh, Emily
    Sipione, Simonetta
    JOURNAL OF NEUROSCIENCE, 2010, 30 (11): : 4072 - 4080
  • [47] TWO CASES OF GM1 GANGLIOSIDOSIS WITH NOVEL MUTATIONS
    Ezgu, F. S.
    Gunduz, M.
    Tuemer, L.
    Fatih, Atuek
    Paschke, E.
    Hasanodlu, A.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 : 157 - 157
  • [48] A Critical Review of Zebrafish Models of Parkinson's Disease
    Doyle, Jillian M.
    Croll, Roger P.
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [49] Epigenetic modifications in Parkinson's disease: A critical review
    Sharma, Ravikant
    Bisht, Priya
    Kesharwani, Anuradha
    Murti, Krishna
    Kumar, Nitesh
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 975
  • [50] The Rationale of Yoga in Parkinson's Disease: A Critical Review
    Mailankody, Pooja
    Varambally, Shivarama
    Thennarasu, K.
    Pal, Pramod Kumar
    NEUROLOGY INDIA, 2021, 69 (05) : 1165 - 1175